Publications by authors named "M Frisinghelli"
Background: Therapeutic approach used for pancreatic ductal adenocarcinoma is usually translated also for the rarer acinar counterpart, which shows a different mutational landscape nevertheless. While dMMR/MSI-H status is rare in the ductal histotype, it appears to be more prevalent in pancreatic acinar cell carcinoma (PACC).
Case Presentation: We report the case of a patient with locally advanced MSI-H PACC in whom the treatment with the anti-PD-1 pembrolizumab, administered as third line, made possible surgical resection, achieving even an exceptional pathological complete response.
Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials.
Clin Oncol (R Coll Radiol)
February 2024
Article Synopsis
- - The study investigates the effectiveness of combining nanoliposomal irinotecan (nal-IRI) with 5-fluorouracil/leucovorin (5-FU/LV) for treating advanced biliary tract cancer, compared to the standard FOLFOX regimen.
- - A systematic review and meta-analysis were conducted using data from major medical databases, focusing on outcomes like progression-free survival and overall survival from randomized trials.
- - Results indicated that the nal-IRI combination significantly reduced disease progression risk and improved overall survival and response rates compared to 5-FU/LV alone, suggesting its potential as a more effective treatment option.
Article Synopsis
- A study looked at how stopping anti-PD1 treatment affects patients with advanced melanoma, focusing on those who stopped without their disease getting worse.
- Researchers checked records from 23 hospitals in Italy and found that out of 237 patients, more than half stopped treatment because their cancer showed complete response (CR).
- After about 21 months of follow-up, a high percentage (85.7%) of patients had no signs of their cancer getting worse after stopping treatment, but some (14.3%) did see their cancer progress again.
The mainstay treatment for patients with immediate resectable pancreatic cancer remains upfront surgery, which represents the only potentially curative strategy. Nevertheless, the majority of patients surgically resected for pancreatic cancer experiences disease relapse, even when a combination adjuvant therapy is offered. Therefore, aiming at improving disease free survival and overall survival of these patients, there is an increasing interest in evaluating the activity and efficacy of neoadjuvant and perioperative treatments.
View Article and Find Full Text PDFBackground: Evidence for the efficacy of radiation therapy for primary liver cancer is growing. In this context, proton therapy (PT) can potentially improve the therapeutic ratio, as demonstrated by recent clinical studies. Here we report the first European clinical experience on the use of PT for primary liver cancer.
View Article and Find Full Text PDF